/
KMDA
$7.36+$0.10 (+1.38%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$418.9M
58M shares
52-week range
$6.50 – $9.35
30% from low
Exchange
NASDAQ
CS
Borrow rate
3.92%
Moderate
Price (6 mo)
Loading chart…
Change+$1.54
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $114.5M | $127.2M | $133.2M | $103.6M | $129.3M | $142.5M | $161.0M | $180.5M |
| Cost of revenue | $73.0M | $77.5M | $85.7M | $73.3M | $82.6M | $87.0M | $91.0M | $104.1M |
| Gross profit | $41.5M | $49.7M | $47.6M | $30.3M | $46.7M | $55.5M | $70.0M | $76.4M |
| Gross margin | 36.2% | 39.1% | 35.7% | 29.3% | 36.1% | 38.9% | 43.5% | 42.3% |
| R&D | $9.7M | $13.1M | $13.6M | $11.4M | $13.2M | $13.9M | $15.2M | $13.0M |
| Operating income | $19.3M | $22.8M | $19.2M | −$696.0K | $4.5M | $10.1M | $20.1M | $26.2M |
| EBITDA | $23.5M | $27.8M | $25.4M | $4.0M | $10.8M | $21.2M | $27.8M | $39.2M |
| Net income | $22.3M | $22.3M | $17.1M | −$2.2M | −$2.3M | $8.3M | $14.5M | $20.2M |
| Net margin | 19.5% | 17.5% | 12.9% | -2.2% | -1.8% | 5.8% | 9.0% | 11.2% |
| EPS (diluted) | 0.55 | 0.57 | 0.41 | -0.05 | -0.05 | 0.15 | 0.25 | 0.37 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $202M | $0.43 | $0.40–$0.46 | 3 |
| 2027 | $222M | $0.61 | $0.52–$0.68 | 3 |
| 2028 | $246M | $0.74 | $0.72–$0.76 | 1 |
| 2029 | $265M | $0.79 | $0.76–$0.81 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$40.82
Price
$7.36
Implied upside
+455%
Peer comparison
Kamada Ltd
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
www.kamada.com- Employees
- 462
- IPO / List date
- May 31, 2013
Held by traders on TradeandTell
No one on the platform currently holds KMDA.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in KMDA as of their last filing.
Insider activity (SEC Form 4)
Dividend history
TTM yield · 6.11% ($0.45/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-03-23 | $0.2500 | 2026-04-07 |
| 2025-03-17 | $0.2000 | 2025-04-07 |
Recent trades on TradeandTell
No one on the platform has traded KMDA yet.
